Staphylococcal Biofilms: Challenges and Novel Therapeutic Perspectives

• Main Authors: Christian Kranjec, Danae Morales Angeles, Marita Torrissen Mårli, Lucía Fernández, Pilar García, Morten Kjos, Dzung Bao Diep
• Format: Article
• Language: English
• Published: MDPI AG 2021-01-01
• Series: Antibiotics
• Subjects: <i>S. aureus</i>; coagulase-negative staphylococci; biofilm; bacteriocins; bacteriophages; antibiotics
• Online Access: https://www.mdpi.com/2079-6382/10/2/131

Staphylococci, like <i>Staphylococcus aureus </i>and <i>S. epidermidis</i>, are common colonizers of the human microbiota. While being harmless in many cases, many virulence factors result in them being opportunistic pathogens and one of the major causes of hospital-acquired infections worldwide. One of these virulence factors is the ability to form biofilms—three-dimensional communities of microorganisms embedded in an extracellular polymeric matrix (EPS). The EPS is composed of polysaccharides, proteins and extracellular DNA, and is finely regulated in response to environmental conditions. This structured environment protects the embedded bacteria from the human immune system and decreases their susceptibility to antimicrobials, making infections caused by staphylococci particularly difficult to treat. With the rise of antibiotic-resistant staphylococci, together with difficulty in removing biofilms, there is a great need for new treatment strategies. The purpose of this review is to provide an overview of our current knowledge of the stages of biofilm development and what difficulties may arise when trying to eradicate staphylococcal biofilms. Furthermore, we look into promising targets and therapeutic methods, including bacteriocins and phage-derived antibiofilm approaches.